| 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. | |
| | |
MedLine Citation:
|
PMID: 11202454 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
In spite of the availability of numerous procedures, diagnostic imaging of tumour manifestations in patients with medullary thyroid carcinoma and elevated calcitonin levels is often difficult. In the present study, the new procedure of fluorine-18 dihydroxyphenylalanine positron emission tomography (18F-DOPA PET) was compared with the established functional and morphological imaging methods. After evaluation of the normal distribution of 18F-DOPA, 11 patients with medullary thyroid carcinoma were examined using 18F-DOPA PET. Results of 18F-fluorodeoxyglucose (18F-FDG) PET, somatostatin receptor scintigraphy (SRS) and morphological tomographic imaging (CT/MRI) were available for all patients. All individual procedures were evaluated without reference to prior information. Data assessment for each patient was based on cooperation between experienced radiologists and specialists in nuclear medicine, who considered all the available findings (histological results, imaging, follow-up studies). This cooperation served as the gold standard against which the results of the individual procedures were evaluated. A total of 27 tumours were studied [three primary tumours (PT)/local recurrence (LR), 16 lymph node metastases (LNM) and eight organ metastases (OM)]. 18F-DOPA PET produced 17 true-positive findings (2 PT/LR, 14 LNM, 1 OM), 18F-FDG PET 12 (2 PT/LR, 7 LNM, 3 OM), SRS 14 (2 PT/LR, 8 LNM, 4 OM) and morphological imaging 22 (3 PT/LR, 11 LNM, 8 OM). The following sensitivities were calculated with respect to total tumour manifestations: 18F-DOPA PET 63%, 18F-FDG PET 44%, SRS 52%, morphological imaging 81%. Thus, the morphological imaging procedures produce the best overall sensitivity, but the specificity for PT/LR (55%) and LNM (57%) was low. With respect to lymph node staging, the best results were obtained with 18F-DOPA PET. 18F-DOPA PET is a new functional imaging procedure for medullary thyroid carcinoma that seems to provide better results than SRS and 18F-FDG PET. Moreover, the data indicate that no single procedure provides adequate diagnostic certainty. Therefore, 18F-DOPA PET is a useful supplement to morphological diagnostic imaging, improving lymph node staging and enabling a more specific diagnosis of primary tumour and local recurrence. |
| | |
Authors:
|
S Hoegerle; C Altehoefer; N Ghanem; I Brink; E Moser; E Nitzsche |
Related Documents
:
|
18555034 - Impact of the introduction of integrated pet-ct into the preoperative staging pathway o... 9662594 - Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphom... 9406694 - Perspectives on oncologic imaging with radiolabeled antibodies. 12584214 - 18f-fluoro-deoxy-glucose positron emission tomography (18f-fdg-pet) for assessment of e... 16554584 - Detection of strictures on upper gastrointestinal tract radiographic examinations after... 18553214 - Tricuspid valve magnetic resonance imaging phase contrast velocity-encoded flow quantif... |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article |
Journal Detail:
|
Title: European journal of nuclear medicine Volume: 28 ISSN: 0340-6997 ISO Abbreviation: Eur J Nucl Med Publication Date: 2001 Jan |
Date Detail:
|
Created Date: 2001-01-30 Completed Date: 2001-03-22 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 7606882 Medline TA: Eur J Nucl Med Country: Germany |
Other Details:
|
Languages: eng Pagination: 64-71 Citation Subset: IM |
Affiliation:
|
Department of Radiology, Albert-Ludwigs University Freiburg, Germany. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Calcitonin / metabolism* Carcinoma, Medullary / metabolism*, radionuclide imaging* Dihydroxyphenylalanine / analogs & derivatives, diagnostic use* Female Fluorodeoxyglucose F18 / diagnostic use Humans Magnetic Resonance Imaging Male Middle Aged Radiopharmaceuticals / diagnostic use* Receptors, Somatostatin / metabolism Thyroid Neoplasms / metabolism*, radionuclide imaging* Tomography, Emission-Computed Tomography, X-Ray Computed |
| Chemical | |
Reg. No./Substance:
|
0/Radiopharmaceuticals; 0/Receptors, Somatostatin; 63-84-3/Dihydroxyphenylalanine; 63503-12-8/Fluorodeoxyglucose F18; 75290-51-6/fluorodopa F 18; 9007-12-9/Calcitonin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Scintimammography with 99mTc-MIBI versus dynamic MRI for non-invasive characterization of breast mas...
Next Document: Activation of the growth plates on three-phase bone scintigraphy: the explanation for the overgrowth...